Literature DB >> 20417035

Efficacy of Cymelarsan and Diminasan against Trypanosoma equiperdum infections in mice and horses.

A Hagos1, B M Goddeeris, K Yilkal, T Alemu, R Fikru, H T Yacob, G Feseha, F Claes.   

Abstract

Trypanocidal sensitivity studies were conducted to assess the efficacy of Diminazene diaceturate (Diminasan) and Bis (aminoethylthio) 4-melaminophenylarsine dihydrochloride (Cymelarsan) against Trypanosoma equiperdum (isolated from two mares with chronic cases of dourine) 713/943 and 834/940 Dodola strains in experimentally infected mice and horses. Diminasan at doses from 3.5 mg/kg to 28 mg/kg and Cymelarsan at doses of 0.25 mg/kg and 0.5 mg/kg body weight failed to cure any of the mice, indicating a clear dose dependent relationship in the mean time of relapse observed in mice. Indeed, mice treated with lower doses relapsed after a shorter time than mice treated with higher doses. However, mice treated with Cymelarsan at doses of 1.0 mg/kg and 2.0 mg/kg body weight were cured and no parasitemia was observed for 60 days. The efficacy of Cymelarsan was also tested in horses. Two groups of horses containing two animals each were infected with T. equiperdum 834/940 Dodola strain and treated with Cymelarsan at a dose rate of 0.25 mg/kg and 0.5 mg/kg, respectively. Cymelarsan at 0.25 mg/kg and 0.5 mg/kg body weight cleared parasitemia within 24 h post treatment and none of the animals were found to show relapse throughout the 320 days of observation. The sensitivity of the particular trypanosome strain to Cymelarsan was also supported by the relative improvement in the mean PCV levels of horses following treatment. A statistically significant difference (p<0.01) in the mean PCV levels of horses treated with Cymelarsan was observed between day 20 at peak parasitemia and days 40 as well as 60 of observation. The mean PCV levels of horses in the control group progressively decreased within the first 60 days of post infection. Two of the horses in the control group developed chronic form of dourine manifested by genital as well as nervous signs with progressive loss of body condition within 320 days post infection. The efficacy of Cymelarsan against the chronic form of dourine was confirmed after treatment of one of the control horses with Cymelarsan at a dose rate of 0.25 mg/kg body weight at day 282 post infection. It was noted that the treated horse improved overall body condition and clinical signs such as incoordination of hind legs, weakness and ventral oedema disappeared within 10 days of treatment. Thus, Cymelarsan was found to be quite effective in curing horses in acute as well as chronic form of dourine. The results obtained from the present study will be important for designing effective control measures against dourine. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417035     DOI: 10.1016/j.vetpar.2010.03.041

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  13 in total

1.  Efficacy of diminazene diaceturate and isometamidium chloride hydrochloride for the treatment of Trypanosoma evansi in mice model.

Authors:  Weldegebrial G Aregawi; Fikadu Gutema; Juhar Tesfaye; Abel Sorsa; Brehanu Megersa; Philimon Teshome; Getahun E Agga; Hagos Ashenafi
Journal:  J Parasit Dis       Date:  2020-10-12

2.  Isolation, cultivation and molecular characterization of a new Trypanosoma equiperdum strain in Mongolia.

Authors:  Keisuke Suganuma; Sandagdorj Narantsatsral; Banzragch Battur; Shino Yamasaki; Davaajav Otgonsuren; Simon Peter Musinguzi; Batdorj Davaasuren; Badgar Battsetseg; Noboru Inoue
Journal:  Parasit Vectors       Date:  2016-08-31       Impact factor: 3.876

Review 3.  The animal trypanosomiases and their chemotherapy: a review.

Authors:  Federica Giordani; Liam J Morrison; Tim G Rowan; Harry P DE Koning; Michael P Barrett
Journal:  Parasitology       Date:  2016-10-10       Impact factor: 3.234

4.  Genome-Wide SNP Analysis Reveals Distinct Origins of Trypanosoma evansi and Trypanosoma equiperdum.

Authors:  Bart Cuypers; Frederik Van den Broeck; Nick Van Reet; Conor J Meehan; Julien Cauchard; Jonathan M Wilkes; Filip Claes; Bruno Goddeeris; Hadush Birhanu; Jean-Claude Dujardin; Kris Laukens; Philippe Büscher; Stijn Deborggraeve
Journal:  Genome Biol Evol       Date:  2017-08-01       Impact factor: 3.416

5.  Antiprotozoal Drug Handling and Management Practices in Asella District, Central Oromia, Ethiopia.

Authors:  Ashenafi Ababu; Dereje Endashaw; Haben Fesseha; Mesfin Mathewos
Journal:  Vet Med Int       Date:  2021-04-19

6.  New Trypanosoma evansi Type B Isolates from Ethiopian Dromedary Camels.

Authors:  Hadush Birhanu; Tadesse Gebrehiwot; Bruno Maria Goddeeris; Philippe Büscher; Nick Van Reet
Journal:  PLoS Negl Trop Dis       Date:  2016-04-01

Review 7.  Dourine: a neglected disease of equids.

Authors:  Yonas Gizaw; Mulisa Megersa; Teka Fayera
Journal:  Trop Anim Health Prod       Date:  2017-04-24       Impact factor: 1.559

8.  The establishment of in vitro culture and drug screening systems for a newly isolated strain of Trypanosoma equiperdum.

Authors:  Keisuke Suganuma; Shino Yamasaki; Nthatisi Innocentia Molefe; Peter Simon Musinguzi; Batdorj Davaasuren; Ehab Mossaad; Sandagdorj Narantsatsral; Banzragch Battur; Badgar Battsetseg; Noboru Inoue
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-04-13       Impact factor: 4.077

9.  Humoral immune response and delayed-type hypersensitivity in rabbits infected with Trypanosoma equiperdum.

Authors:  Tiziana Di Febo; Ivanka Krasteva; Barbara Bonfini; Manuela Tittarelli; Osvaldo Matteucci; Gianluca Orsini; Emanuela Rossi; Michele Podaliri Vulpiani; Diamante Rodomonti; Luigi Iannetti; Mirella Luciani
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

10.  Isometamidium chloride and homidium chloride fail to cure mice infected with Ethiopian Trypanosoma evansi type A and B.

Authors:  Gebrekrustos Mekonnen; Elmi Fahiye Mohammed; Weldu Kidane; Awol Nesibu; Hagos Yohannes; Nick Van Reet; Philippe Büscher; Hadush Birhanu
Journal:  PLoS Negl Trop Dis       Date:  2018-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.